Background Data from previous studies of the MVC-COV1901 vaccine, a subunit vaccine
against SARS-CoV-2 based on the stable prefusion spike protein (S-2P) adjuvanted with …

Background MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised
spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to …

Background The development of effective vaccines against coronavirus disease 2019 is a
global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus …

Background This was a phase 1, dose-escalation open-label trial to evaluate the safety and
immunogenicity of MVCCOV1901, a SARS-CoV-2 S-2P protein vaccine adjuvanted with …

Background The ongoing COVID-19 pandemic has had a significant impact worldwide, with
an incommensurable social and economic burden. The rapid development of safe and …

Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®,
an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity …

Introduction MVC-COV1901 is a protein subunit COVID-19 vaccine based on the stable
prefusion spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. Interim …

Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are actively carried out around the world. Several vaccines are currently …

Background: The development of vaccines to control the coronavirus disease 2019 (COVID-
19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute …

Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been evaluated in clinical trials. However, trials addressing the immune response in …